Sugi Predict

Sugi Predict / Compounds / SCHEMBL1194342

SCHEMBL1194342

SCHEMBL1194342

CCOC(=O)c1sc(C)nc1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.43
▸ ALDH1A1 P00352 6/20 0.41
▸ HPGD P15428 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ CRHBP P24387 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ TRPM8 Q7Z2W7 3/20 0.40
▸ CYP2C9 P11712 1/20 0.39
▸ CDC7 O00311 3/20 0.39
▸ DBF4 Q9UBU7 3/20 0.39
▸ ROCK2 O75116 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18720471 0.86 RAB9A (0.35) NPC1ALDH1A1HPGDHSD17B10GAA
SCHEMBL6336462 0.82 CDC7 (0.61) ALDH1A1HSD17B10MEN1KMT2AMAPT
SCHEMBL26100860 0.82 ALDH1A1 (0.38) ALDH1A1HPGDHSD17B10CYP1A2MEN1
SCHEMBL15049083 0.81 TRPM8 (0.60) ALDH1A1GAAMEN1KMT2AMAPT
SCHEMBL15048987 0.80 TRPM8 (0.63) NPC1ALDH1A1MEN1KMT2AMAPT
SCHEMBL5237288 0.80 CDC7 (0.68) MEN1KMT2AMAPTKDM4EHSP90AA1
SCHEMBL15049133 0.79 TRPM8 (0.61) NPC1MEN1KMT2AMAPTKDM4E
SCHEMBL26639123 0.78 CDC7 (0.43) MEN1KMT2AMAPTKDM4EHSP90AA1
SCHEMBL9199237 0.77 NPC1 (0.49) NPC1ALDH1A1HPGDHSD17B10GAA
SCHEMBL15049533 0.77 TRPM8 (0.66) MEN1KMT2AMAPTKDM4EHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132127-A1 NOVEL SPIRO COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-05-14 — — US disclosed
WO-2024233848-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2024-11-14 — — WO disclosed
EP-4430022-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE Vigil Neuroscience, Inc. (US) 2024-09-18 — — EP disclosed
CN-118176179-A Novel spiro compounds 田边三菱制药株式会社 2024-06-11 — — CN disclosed
WO-2023086801-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2023-05-19 — — WO disclosed
WO-2023074847-A1 NOVEL SPIRO COMPOUND 田辺三菱製薬株式会社 2023-05-04 — — WO disclosed
WO-2023074847-A1 NOVEL SPIRO COMPOUND 田辺三菱製薬株式会社 2023-05-04 — — WO disclosed
EP-2150251-B9 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC (US) 2013-02-27 — — EP disclosed
EP-2150251-B1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC (US) 2012-06-27 — — EP disclosed
US-8168633-B2 Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase GENENTECH, INC. (US) 2012-05-01 — — US disclosed
US-7893060-B2 Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase F. HOFFMANN-LA ROCHE AG (GB) 2011-02-22 — — US disclosed
US-20100190769-A1 THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE F. HOFFMANN-LA ROCHE AG (CH) 2010-07-29 — — US disclosed
US-20100190769-A1 THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE F. HOFFMANN-LA ROCHE AG (CH) 2010-07-29 — — US disclosed
US-20100190769-A1 THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE F. HOFFMANN-LA ROCHE AG (CH) 2010-07-29 — — US disclosed
EP-2158207-A1 THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE F. Hoffmann-Roche AG (CH) 2010-03-03 — — EP disclosed
EP-2150251-A1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-10 — — EP disclosed
US-20090156633-A1 Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity AMGEN INC. (US) 2009-06-18 — — US disclosed
WO-2008152390-A1 THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE F.HOFFMANN-LA ROCHE AG (CH) 2008-12-18 — — WO disclosed
WO-2008152390-A1 THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE F.HOFFMANN-LA ROCHE AG (CH) 2008-12-18 — — WO disclosed
WO-2008137060-A1 THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190769-A1 THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE PDPK1, PIK3CA, PI4KA NPC1 3140/4885ALDH1A1 1436/4885HPGD 3170/4885
US-20090156633-A1 Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity EGLN3, HIF1AN, EGLN2 NPC1 1769/4885ALDH1A1 108/4885HPGD 16/4885
US-20260132127-A1 NOVEL SPIRO COMPOUND TRHR, NR3C2, THRB NPC1 457/4885ALDH1A1 1063/4885HPGD 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.